HK1232220A1 - 用於治療心血管疾病的 -苄基異喹啉衍生物 - Google Patents

用於治療心血管疾病的 -苄基異喹啉衍生物

Info

Publication number
HK1232220A1
HK1232220A1 HK17105829.7A HK17105829A HK1232220A1 HK 1232220 A1 HK1232220 A1 HK 1232220A1 HK 17105829 A HK17105829 A HK 17105829A HK 1232220 A1 HK1232220 A1 HK 1232220A1
Authority
HK
Hong Kong
Prior art keywords
benzylisoquinoline
derivatives
treatment
cardiovascular diseases
cardiovascular
Prior art date
Application number
HK17105829.7A
Other languages
English (en)
Inventor
Stefano Chimenti
Christine Courchay
Aime Dessinges
Franoise Gellibert
Bertrand Goument
Marc Konnert
Jean Louis Peglion
Christophe Poitevin
Jean Paul Vilaine
Nicole Villeneuve
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of HK1232220A1 publication Critical patent/HK1232220A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK17105829.7A 2014-02-21 2017-06-13 用於治療心血管疾病的 -苄基異喹啉衍生物 HK1232220A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1451389A FR3017868A1 (fr) 2014-02-21 2014-02-21 Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2015/050415 WO2015124877A1 (fr) 2014-02-21 2015-02-20 Dérivés de 5-benzylisoquinoléine pour le traitement de maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
HK1232220A1 true HK1232220A1 (zh) 2018-01-05

Family

ID=50424640

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105829.7A HK1232220A1 (zh) 2014-02-21 2017-06-13 用於治療心血管疾病的 -苄基異喹啉衍生物

Country Status (38)

Country Link
US (1) US9809553B2 (zh)
EP (1) EP3107900B1 (zh)
JP (1) JP6491226B2 (zh)
KR (1) KR102251198B1 (zh)
CN (1) CN105980361B (zh)
AR (1) AR099493A1 (zh)
AU (1) AU2015220659B2 (zh)
BR (1) BR112016017679B1 (zh)
CA (1) CA2938344C (zh)
CL (1) CL2016002089A1 (zh)
CY (1) CY1120034T1 (zh)
DK (1) DK3107900T3 (zh)
EA (1) EA030617B1 (zh)
ES (1) ES2659885T3 (zh)
FR (1) FR3017868A1 (zh)
HK (1) HK1232220A1 (zh)
HR (1) HRP20180141T1 (zh)
HU (1) HUE038337T2 (zh)
IL (1) IL246721B (zh)
JO (1) JO3372B1 (zh)
LT (1) LT3107900T (zh)
MA (1) MA39207A1 (zh)
ME (1) ME02863B (zh)
MX (1) MX363301B (zh)
MY (1) MY178745A (zh)
NO (1) NO3107900T3 (zh)
NZ (1) NZ722513A (zh)
PL (1) PL3107900T3 (zh)
PT (1) PT3107900T (zh)
RS (1) RS56766B1 (zh)
RU (1) RU2679621C2 (zh)
SG (1) SG11201605662TA (zh)
SI (1) SI3107900T1 (zh)
TW (1) TWI547484B (zh)
UA (1) UA117953C2 (zh)
UY (1) UY35997A (zh)
WO (1) WO2015124877A1 (zh)
ZA (1) ZA201604976B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026756C (en) * 2016-06-17 2021-03-02 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
MA52813A (fr) * 2018-06-07 2021-04-14 Disarm Therapeutics Inc Inhibiteurs de sarm1
JP2021529830A (ja) * 2018-07-02 2021-11-04 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） ラクテート増強化合物及びその使用
BR112021008883A2 (pt) 2018-11-06 2021-08-10 Cervello Therapeutics, Llc inibidores de rock quinase
US11248004B2 (en) 2018-11-06 2022-02-15 Cervello Therapeutics, Llc. Substituted isoquinolines as rock kinase inhibitors
PE20220261A1 (es) 2019-03-22 2022-02-22 Saniona As Inhibidores del canal de potasio novedosos
EP4051680A1 (en) 2019-10-30 2022-09-07 Biogen MA Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
DE60045890D1 (de) 1999-04-27 2011-06-09 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
AU2001288242B2 (en) * 2000-08-11 2005-11-17 Purdue Research Foundation Process for the preparation of dinapsoline
TWI329108B (en) * 2001-09-06 2010-08-21 Schering Corp 17-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
NZ565040A (en) * 2005-06-28 2010-05-28 Sanofi Aventis Isoquinoline derivatives as inhibitors of RHO-kinase
CA2615577C (en) 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
CA2615663C (en) 2005-07-26 2013-10-15 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
CN101573354B (zh) * 2006-12-27 2014-02-12 塞诺菲-安万特股份有限公司 取代的异喹啉类及其作为Rho-激酶抑制剂的用途
ES2364511T3 (es) 2006-12-27 2011-09-05 Sanofi Derivados de isoquinolona e isoquinolinona sustituidos con cicloalquilamina.
NZ577981A (en) 2006-12-27 2011-12-22 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
KR101494452B1 (ko) 2006-12-27 2015-02-16 사노피 사이클로알킬아민 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
WO2008077554A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
CL2008000973A1 (es) * 2007-04-05 2009-01-02 Astrazeneca Ab Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
CA2728137C (en) 2008-06-24 2016-10-18 Sanofi-Aventis Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
CN102131785B (zh) 2008-06-24 2014-10-29 赛诺菲-安万特 6-取代的异喹啉和异喹啉酮
KR101692211B1 (ko) 2008-06-24 2017-01-03 사노피 Ｒｈｏ 키나제 억제제로서의 비사이클릭 및 폴리사이클릭 치환된 이소퀴놀린 및 이소퀴놀리논 유도체

Also Published As

Publication number Publication date
HUE038337T2 (hu) 2018-10-29
PL3107900T3 (pl) 2018-04-30
US20170137385A1 (en) 2017-05-18
MX363301B (es) 2019-03-20
CA2938344C (fr) 2018-07-03
KR102251198B1 (ko) 2021-05-11
US9809553B2 (en) 2017-11-07
BR112016017679A2 (zh) 2017-08-08
IL246721B (en) 2018-12-31
EA030617B1 (ru) 2018-08-31
JP6491226B2 (ja) 2019-03-27
RS56766B1 (sr) 2018-04-30
AU2015220659A1 (en) 2016-08-04
CL2016002089A1 (es) 2017-01-27
JO3372B1 (ar) 2019-03-13
TWI547484B (zh) 2016-09-01
MY178745A (en) 2020-10-20
KR20160116003A (ko) 2016-10-06
EP3107900A1 (fr) 2016-12-28
AU2015220659B2 (en) 2018-09-13
BR112016017679B1 (pt) 2022-07-26
RU2016137502A (ru) 2018-03-27
TW201534587A (zh) 2015-09-16
ES2659885T3 (es) 2018-03-19
EA201691675A1 (ru) 2017-02-28
JP2017506251A (ja) 2017-03-02
UY35997A (es) 2015-08-31
FR3017868A1 (fr) 2015-08-28
AR099493A1 (es) 2016-07-27
SG11201605662TA (en) 2016-08-30
RU2679621C2 (ru) 2019-02-12
PT3107900T (pt) 2018-01-08
CY1120034T1 (el) 2018-12-12
CN105980361B (zh) 2019-05-21
ME02863B (me) 2018-04-20
HRP20180141T1 (hr) 2018-03-09
CA2938344A1 (fr) 2015-08-27
SI3107900T1 (en) 2018-02-28
DK3107900T3 (en) 2018-02-19
ZA201604976B (en) 2022-05-25
MA39207A1 (fr) 2017-04-28
WO2015124877A1 (fr) 2015-08-27
MX2016010779A (es) 2016-10-26
NO3107900T3 (zh) 2018-04-14
NZ722513A (en) 2019-08-30
UA117953C2 (uk) 2018-10-25
CN105980361A (zh) 2016-09-28
RU2016137502A3 (zh) 2018-09-24
LT3107900T (lt) 2017-12-27
EP3107900B1 (fr) 2017-11-15

Similar Documents

Publication Publication Date Title
IL279627A (en) A method for treating depression
IL253945B (en) kdm1a inhibitors to treat the disease
HK1232147A1 (zh) 用於治療纖維化的賽尼克韋羅
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
RS63231B1 (sr) Primena derivata hinolina u lečenju upalnih bolesti
RS61536B1 (sr) Kombinacije fgfr- i cmet-inhibitora za lečenje kancera
HK1232220A1 (zh) 用於治療心血管疾病的 -苄基異喹啉衍生物
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
SG11201702700UA (en) Methods for the treatment of peri-implantitis
SG11201609522TA (en) Methods for treating cardiovascular diseases
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
HUE040039T2 (hu) Az 5-fluor-triptofol elõállítására szolgáló eljárás
GB201412010D0 (en) Treatment of hypertransaminasemia
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF 20180921: (54) 5-BENZYLISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES